Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.84 |
| ▸ | RAB9A | P51151 | 7/20 | 0.84 |
| ▸ | MAPT | P10636 | 6/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.84 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.81 |
| ▸ | MEN1 | O00255 | 7/20 | 0.81 |
| ▸ | HTT | P42858 | 1/20 | 0.81 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.81 |
| ▸ | CA12 | O43570 | 3/20 | 0.70 |
| ▸ | CA1 | P00915 | 3/20 | 0.70 |
| ▸ | CA2 | P00918 | 3/20 | 0.70 |
| ▸ | CA9 | Q16790 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | TP53 | P04637 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1719786 | 0.92 | RAB9A (1.00) | NPC1RAB9AMAPTSMN1; SMN2TAAR1 | |
| SCHEMBL4110351 | 0.92 | NPC1 (0.72) | NPC1RAB9AMAPTSMN1; SMN2TAAR1 | |
| SCHEMBL23069090 | 0.91 | NPC1 (0.71) | NPC1RAB9AMAPTSMN1; SMN2TAAR1 | |
| SCHEMBL4111833 | 0.90 | MEN1 (1.00) | NPC1RAB9AMAPTSMN1; SMN2TAAR1 | |
| SCHEMBL5974188 | 0.90 | MAPT (0.70) | NPC1RAB9AMAPTSMN1; SMN2TAAR1 | |
| SCHEMBL4106292 | 0.90 | ALDH1A1 (0.71) | NPC1RAB9AMAPTSMN1; SMN2TAAR1 | |
| SCHEMBL4921279 | 0.90 | NPC1 (0.70) | NPC1RAB9AMAPTSMN1; SMN2TAAR1 | |
| SCHEMBL24166921 | 0.89 | NPC1 (0.69) | NPC1RAB9AMAPTSMN1; SMN2TAAR1 | |
| SCHEMBL4112101 | 0.88 | MAPT (0.74) | NPC1RAB9AMAPTSMN1; SMN2TAAR1 | |
| SCHEMBL4107272 | 0.87 | MAPT (0.66) | NPC1RAB9AMAPTSMN1; SMN2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | claimed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | claimed |
| WO-2003006426-A1 | AROMATIC GUANYLHYDRAZONES AS EFFECTIVE COMPOUNDS AGAINST NEURODISEASES | AXXIMA PHARMACEUTICALS AG (DE) | 2003-01-23 | — | — | WO | claimed |
| US-8765802-B2 | Kinase inhibitors, compositions thereof, and methods of use therewith | PROVID PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | disclosed |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | disclosed |
| EP-2155675-A1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | Provid Pharmaceuticals, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090018141-A1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | PROVID PHARMACEUTICALS, INC. | 2009-01-15 | — | — | US | disclosed |
| WO-2008156573-A1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | PROVID PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1786422-A2 | ARYL UREA DERIVATIVES FOR TREATING OBESITY | Prosidion Limited (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006018662-A2 | ARYL UREA DERIVATIVES FOR TREATING OBESITY | PROSIDION LIMITED (GB) | 2006-02-23 | — | — | WO | disclosed |
| US-20050187409-A1 | Inhibitors of RNase P proteins as antibacterial compounds | POWERS GORDON D (US) | 2005-08-25 | — | — | US | disclosed |
| WO-2003006426-A1 | AROMATIC GUANYLHYDRAZONES AS EFFECTIVE COMPOUNDS AGAINST NEURODISEASES | AXXIMA PHARMACEUTICALS AG (DE) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | NPC1 148/4885RAB9A 3359/4885MAPT 4151/4885 |
| US-20050187409-A1 | Inhibitors of RNase P proteins as antibacterial compounds | RNASEH1, RNASEL, RNASE1 | NPC1 2983/4885RAB9A 2257/4885MAPT 3967/4885 |
| US-20090018141-A1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | CHEK2, ATM, CHEK1 | NPC1 3750/4885RAB9A 2366/4885MAPT 2088/4885 |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | NPC1 148/4885RAB9A 3359/4885MAPT 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.